Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma.
Nokin MJ, Darbo E, Richard E, San José S, de Hita S, Prouzet-Mauleon V, Turcq B, Gerardelli L, Crake R, Velasco V, Koopmansch B, Lambert F, Xue JY, Sang B, Horne J, Ziemons E, Villanueva A, Blomme A, Herfs M, Cataldo D, Calvayrac O, Porporato P, Nadal E, Lito P, Jänne PA, Ricciuti B, Awad MM, Ambrogio C, Santamaría D; Bolero Consortium. Nokin MJ, et al. Among authors: calvayrac o. Cell Rep Med. 2024 Aug 20;5(8):101663. doi: 10.1016/j.xcrm.2024.101663. Epub 2024 Aug 1. Cell Rep Med. 2024. PMID: 39094577 Free PMC article.
Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies.
Figarol S, Delahaye C, Gence R, Doussine A, Cerapio JP, Brachais M, Tardy C, Béry N, Asslan R, Colinge J, Villemin JP, Maraver A, Ferrer I, Paz-Ares L, Kessler L, Burrows F, Lajoie-Mazenc I, Dongay V, Morin C, Florent A, Pagano S, Taranchon-Clermont E, Casanova A, Pradines A, Mazieres J, Favre G, Calvayrac O. Figarol S, et al. Among authors: calvayrac o. Nat Commun. 2024 Jun 27;15(1):5345. doi: 10.1038/s41467-024-49360-4. Nat Commun. 2024. PMID: 38937474 Free PMC article.
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma.
Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol JL, Calvayrac O, Moll HP, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong KK, Yarden Y, Casanova E, Soria JC, Colinge J, Siebel CW, Mazieres J, Favre G, Paz-Ares L, Maraver A. Bousquet Mur E, et al. Among authors: calvayrac o. J Clin Invest. 2020 Feb 3;130(2):612-624. doi: 10.1172/JCI126896. J Clin Invest. 2020. PMID: 31671073 Free PMC article.
Cytoplasmic p27Kip1 promotes tumorigenesis via suppression of RhoB activity.
Calvayrac O, Nowosad A, Cabantous S, Lin LP, Figarol S, Jeannot P, Serres MP, Callot C, Perchey RT, Creff J, Taranchon-Clermont E, Rouquette I, Favre G, Pradines A, Manenti S, Mazieres J, Lee H, Besson A. Calvayrac O, et al. J Pathol. 2019 Jan;247(1):60-71. doi: 10.1002/path.5167. Epub 2018 Dec 11. J Pathol. 2019. PMID: 30206932
Molecular biomarkers for lung adenocarcinoma.
Calvayrac O, Pradines A, Pons E, Mazières J, Guibert N. Calvayrac O, et al. Eur Respir J. 2017 Apr 5;49(4):1601734. doi: 10.1183/13993003.01734-2016. Print 2017 Apr. Eur Respir J. 2017. PMID: 28381431 Free article. Review.
The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism.
Calvayrac O, Mazières J, Figarol S, Marty-Detraves C, Raymond-Letron I, Bousquet E, Farella M, Clermont-Taranchon E, Milia J, Rouquette I, Guibert N, Lusque A, Cadranel J, Mathiot N, Savina A, Pradines A, Favre G. Calvayrac O, et al. EMBO Mol Med. 2017 Feb;9(2):238-250. doi: 10.15252/emmm.201606646. EMBO Mol Med. 2017. PMID: 28003335 Free PMC article.
26 results